CRPC w/ Bone Metastases - Results from #260

REVIEW UroToday

Metabolism and pharmacokinetics of radium-223 in prostate cancer - Abstract April 6, 2015

Hematologic toxicity of concurrent administration of Radium-223 and next-generation antiandrogen therapies - Abstract March 24, 2015

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup February 27, 2015

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights February 27, 2015

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights February 27, 2015

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights February 27, 2015

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights February 27, 2015

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights February 27, 2015

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA February 27, 2015

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights February 27, 2015

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights February 26, 2015

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial February 26, 2015

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights February 26, 2015

Bayer presents latest oncology research at ASCO GU 2015 February 25, 2015

Radium-223 dichloride for metastatic castration-resistant prostate cancer: The urologist's perspective - Abstract February 25, 2015

Cancer therapy using unsealed radioisotopes-the present and future - Abstract February 4, 2015

Radium-223 dichloride: A novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases - Abstract January 31, 2015

Radium-223 dichloride: A new paradigm in the treatment of prostate cancer - Abstract January 29, 2015

Targeted radionuclide therapy for castration-resistant prostate cancer - Abstract January 27, 2015

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223 - Abstract January 16, 2015

Page 14 of 15